Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960,[1] but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug.[2][3][4][5][6][7][8]
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one or "iso-flubromazepam",[9] may have been sold under the same name.[2]
^US 3136815, "Amino substituted benzophenone oximes and derivatives thereof"
^ abMoosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V (November 2013). "Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics". Journal of Mass Spectrometry. 48 (11): 1150–9. Bibcode:2013JMSp...48.1150M. doi:10.1002/jms.3279. PMID24259203.
^"Flubromazepam". New Synthetic Drugs Database. 12 November 2023.
^Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645. doi:10.1002/dta.2003. PMID27366870.
^Høiseth G, Tuv SS, Karinen R (November 2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. doi:10.1016/j.forsciint.2016.09.006. PMID27685473.